TMDX TransMedics Group, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1756262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.5%
TTM net income YoY57.4%
TTM EPS YoY48.0%
Revenue 3-yr CAGR56.0%
Net income 3-yr CAGR—
Margins
Gross margin58.6%
Operating margin11.9%
Net margin19.9%
FCF margin6.1%
EBITDA margin17.4%
Returns
ROE31.9%
ROA11.7%
ROIC (approx.)—
Asset turnover0.59x
Leverage & solvency
Liabilities / assets63.7%
Debt / equity0.00x
Current ratio4.53x
Interest coverage3.46x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio2.6%
Payout ratio—
Capex / revenue9.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $605.49M | $441.54M |
| Cost of revenue | $242.69M | $179.46M |
| Gross profit | $362.81M | $262.08M |
| R&D expense | $69.06M | $55.97M |
| SG&A expense | $185.17M | $168.62M |
| Operating income | $108.58M | $37.50M |
| Interest expense | $13.78M | $14.41M |
| Pretax income | $107.52M | $35.78M |
| Income tax | -$82.77M | $316,000 |
| Net income | $190.29M | $35.46M |
| EBITDA | $135.77M | $57.25M |
| EPS (basic) | 5.60 | 1.07 |
| EPS (diluted) | 4.87 | 1.01 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 40.54M | 35.22M |
| Balance sheet | ||
| Cash & equivalents | $488.87M | $337.15M |
| Receivables | $84.28M | $97.72M |
| Inventory | $48.88M | $46.55M |
| Current assets | $637.78M | $497.22M |
| PP&E, net | $327.66M | $285.97M |
| Goodwill | $11.55M | $11.55M |
| Intangibles | $1.95M | $2.15M |
| Total assets | $1.07B | $804.08M |
| Current liabilities | $89.31M | $59.91M |
| Short-term debt | $10.00M | — |
| Total liabilities | $595.27M | $575.47M |
| Shareholders' equity | $473.10M | $228.60M |
| Shares outstanding | 34.27M | 33.62M |
| Cash flow statement | ||
| Operating cash flow | $192.84M | $48.80M |
| Capital expenditure | $59.25M | $129.74M |
| Free cash flow | $133.59M | -$80.94M |
| Investing cash flow | -$59.25M | -$129.30M |
| Financing cash flow | $16.86M | $22.87M |
| Depreciation & amortization | $27.18M | $19.76M |
| Stock-based compensation | $36.86M | $33.22M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.